Waldenstrom's macroglobulinemia in the era of immunotherapy
- 21 January 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (6), 1292-1304
- https://doi.org/10.1080/10428194.2020.1711901
Abstract
Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that presents with symptomatic anemia, thrombocytopenia, constitutional symptoms, extramedullary disease and rarely hyperviscosity syndrome. The presence of both IgM monoclonal protein and ≥10% monoclonal lymphoplasmacytic cells is required for the diagnosis. MyD88 is present in 67-90% of patients but is not pathognomonic for WM. Many patients who fulfill the criteria of WM are asymptomatic and do not require treatment. Recent advances in the understanding of the biology of WM have paved the way for new treatment options. The use of novel agents with or without rituximab enables the use of effective chemotherapy-free regiments upfront and in the relapsed setting. New targeted treatments such as venetoclax and CXCR4 antagonists are being investigated.This publication has 110 references indexed in Scilit:
- Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron AdministrationClinical Lymphoma Myeloma and Leukemia, 2013
- Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemiaHaematologica, 2012
- Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2011
- THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIAMediterranean Journal of Hematology and Infectious Diseases, 2011
- Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2010
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Renal Lesions Associated with IgM-Secreting Monoclonal ProliferationsClinical Journal of the American Society of Nephrology, 2008
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003